NYSE: $JNJ A New Frontier in Prostate Cancer Research In a significant development for oncology, Johnson & Johnson has released positive results from its clinical trials concerning an investigational immunotherapy drug known as pasritamig. The findings, which focus on its application in treating prostate-specific antigen (PSA) levels, offer a glimmer of hope for patients facing…